Back to results
US 2025/0367193 A1Published application
Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
AssigneeNikang Therapeutics, Inc.
InventorsYan LOU, Zhiyong YU
Life of this patent
Estimating the term…
Abstract
The present disclosure provides certain bifunctional compounds containing substituted pyrimidine derivatives substituted at the 4-position with a cyclic group that cause degradation of Cyclin-dependent kinase 2 (CDK2) via ubiquitin proteasome pathway and are therefore useful for the treatment of diseases mediated by CDK2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Claims17
A compound of Formula (IA′):
- wherein:
- Degron is an E3 ligase ligand selected from:
- (a) a group of formula (i):
- (b) a group of formula (ii):
- (c) a group of formula (iii):
- (d) a group of formula (iv):
- (e) a group of formula (v):
- and
- (f) a group of formula (vi):
- where:
- Rx is hydrogen, alkyl, cycloalkyl, or alkylcarbonyloxy;
- Ya is CH or N;
- Za is a bond, —CH2—, —NH—, O, or —NHC(O)— where NH of —NHC(O)— is attached to Ya;
- ring A of the E3 ligase ligand of formula (i) is a group of formula (a), (b), or (c):
- where:
- Raa, Rbb, Rcc, and Rdd are independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;
- R4 and R5 are independently hydrogen or alkyl;
- or R4 and R5 together with the carbon to which they are attached form >C═O;
- and
- R6 is hydrogen or alkyl;
- ring B of the E3 ligase ligand of formula (ii) is phenylene, cyclylaminylene, a 5- or 6-membered monocyclic heteroarylene, or a 9- or 10-membered fused bicyclic heteroarylene, wherein each heteroarylene ring contains one to three nitrogen ring atoms and further wherein the phenylene, cyclylaminylene, and each heteroarylene are independently substituted with Ree and Rff independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, and cyano;
- and
- X1, X2, X3 and X4 are independently a bond, -alkylene-, —O—, —(O-alkylene)-, -(alkylene-O)—, —(NRgg-alkylene)-, -(alkylene-NRhh)—,
- —NH—, —N(alkyl)-, —C(═O)—, —NRjjC(═O)—, or —C(═O)NRkk— where Rgg, Rhh, Rjj, and Rkk are independently hydrogen, alkyl, or cycloalkyl and each alkylene is optionally substituted with one or two fluoro;
- Ry is alkyl, hydroalkyl, cycloalkyl or heterocyclyl wherein cycloalkyl and heterocyclyl are substituted with Ra selected from hydrogen, halo, cyano, alkylcarbonyl, and alkylcarbonylamino;
- and
- Wa is bond, O, S, or alkylene;
- Hy is cycloalkylene, arylene, heterocyclylene, bicyclic heterocyclylene, spiro heterocyclylene, bridged heterocyclylene, or fused heterocyclylene, where each of the aforementioned rings is substituted with Rb, Rc, and Rd independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, alkoxy, hydroxy, and cyano;
- R is alkyl, halo, haloalkyl, cycloalkyl, or cyano;
- Q1 is a bond, —O— or —N(R1)— where R1 is hydrogen or alkyl;
- Q2 is a bond or alkylene;
- ring J is aryl, heteroaryl, cycloalkyl, spiro cycloalkyl, fused cycloalkyl, bridged cycloalkyl, heterocyclyl, spiro heterocyclyl, fused heterocyclyl, or bridged heterocyclyl, provided that when Q1 and Q2 are bond, and ring J is heteroaryl, then the heteroaryl of ring J is other than pyrazolyl and imidazolyl substituted with R1a, R2a, R3a, and R4a;
- R1a, R2a, R3a, and R4a are independently selected from hydrogen, deuterium, alkyl, alkylidenyl, cycloalkyl, cycloalkylalkyl, halo, haloalkyl, hydroxy, alkoxy, cyano, hydroxyalkyl, aralkyl, heteroaralkyl, amino, heterocyclyl, or heterocyclylalkyl, wherein the cycloalkyl, heterocyclyl, and the ring portion of cycloalkylalkyl, aralkyl, and heterocyclylalkyl are substituted with Re, Rf, and Rg independently selected from hydrogen, deuterium, alkyl, halo, haloalkyl, cycloalkyl, cyano, hydroxy, amino, alkoxy, acyl, aminocarbonyl, and carboxy;
- and
- L is —Z1—Z2—Z3—Z4—Z5—Z6— where:
- Z1 is a bond, alkylene, —C(O)NR—, —NR′(CO)—, —S(O)2NR—, —NR′S(O)2—, —(O-alkylene)a-, -(alkylene-O)a—, phenylene, monocyclic heteroarylene, or heterocyclylene, where each ring is substituted with Rh and Ri independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
- Z2 is a bond, alkylene, alkynylene, —C(O)—, —C(O)N(R)—, —NR′(CO)—, —(O-alkylene)b-, -(alkylene-O)b—, —O(CH2)7—, —O(CH2)8—, cycloalkylene, or -heterocyclylene, where each ring is substituted with Rj and Rk independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
- Z3 is a bond, alkylene, alkynylene, —C(O)NR—, —NR′(CO)—, —O—, —NR″—, —(O-alkylene)c-, -(alkylene-O)c—, cycloalkylene, spiro cyclolalkylene, phenylene, monocyclic heteroarylene, heterocyclylene, bicyclic heterocyclylene, bridged heterocyclylene, fused heterocyclylene, spiro heterocyclylene, or 11 to 13 membered spiro heterocyclylene, where each ring is substituted with Rm and Rn independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy;
- Z4 is a bond, alkylene, alkynylene, -(alkylene-NR″)—, —O—, —C(O)—, —NR″—, —(O-alkylene)a-, -(alkylene-O)a—, cycloalkylene, spiro cyclolalkylene, phenylene, heteroarylene, heterocyclylene, fused heterocyclylene, bridged heterocyclylene, or spiro heterocyclylene, where each ring is substituted with Ro and Rp independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, cyano, hydroxy, amino, alkylamino, and dialkylamino;
- Z5 is a bond, -alkylene, —NR″—, —O—, —C(O)—, —S(O)2—, —NR′(CO)—, —C(O)NR—, phenylene, monocyclic heteroarylene, or heterocycylene, where each ring is substituted with Rq and Rr independently selected from hydrogen, deuterium, alkyl, alkoxy, halo, haloalkyl, and haloalkoxy, and
- Z6 is a bond, alkylene, —NR″—, —O—, -(alkylene-O)—, —C(O)—, —S(O)2—, —NR′(CO)—, or —C(O)NR—;
- where each R, R′ and R″ is independently hydrogen or alkyl, each a, b, c, and d is independently an integer selected from 1 to 6, and each alkylene of —Z1—, —Z2—, —Z3—, —Z4—, —Z5— and —Z6— is substituted with Rs and Rt where Rs is hydrogen and deuterium and Rt is hydrogen, deuterium, haloalkyl, hydroxy, alkoxy, cyano, cycloalkyl, heterocyclyl, aryl, or monocyclic heteroaryl, wherein cycloalkyl, heterocyclyl, aryl, monocyclic heteroaryl are substituted with one or two substituents independently selected from hydrogen, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, or cyano;
- provided that at least one of —Z1—Z2—Z3—Z4—Z5—Z6— is not a bond;
- or
- a pharmaceutically acceptable salt thereof.
42 more elements
Dependencies are inferred from the claim text.